Yahoo Web Search

  1. Yahoo Finance Results

  2. Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors

    Zacks via Yahoo FinanceOct 03 20:51 PM

    Gilead Sciences, Inc. GILD announced that it entered into a collaboration agreement with HiFiBiO Therapeutics. Both companies have entered into a research collaboration and license agreement ...

  3. Johnson & Johnson JNJ announced long-term data from a late-stage study on Symtuza in HIV-1 patients who are virologically suppressed. Switching to J&J’s HIV treatment helped to maintain high ...

    40.42-0.08 (-0.20%)

    at Tue, Oct 23, 2018, 12:04PM EST - U.S. Markets close in 2 hrs 56 mins

    Nasdaq Real Time Price

    • Open 40.14
    • High 40.64
    • Low 40.12
    • Prev. Close 40.50
    • 52 Wk. High 34.52
    • 52 Wk. Low 34.52
    • P/E 45.72
    • Mkt. Cap 99.41B
  4. This week was a relatively quiet one for the pharma sector ahead of earnings. In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug ...

  5. Gilead Announces Positive Data From Ongoing Biktarvy Study

    Zacks via Yahoo FinanceOct 05 13:55 PM

    Gilead Sciences, Inc. GILD announced positive 96-week results from a phase III study on Biktarvy. The results from the ongoing study showed that Biktarvy was found to be statistically non-inferior ...

  6. (MRK) : Free Stock Analysis Report GlaxoSmithKline plc (GSK) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report To read this article on ...

  7. Edited Transcript of GSK.L earnings conference call or presentation 25-Jul-18 1:15pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceOct 14 9:57 AM

    Q2 2018 GlaxoSmithKline PLC Earnings Call and R&D Update London Oct 14, 2018 (Thomson StreetEvents) -- Edited Transcript of GlaxoSmithKline PLC earnings conference ...

  8. The mid-stage trial was a multicenter, multinational, randomized, placebo-controlled, double-blind,12-month study to assess safety and efficacy of the anti-P-selectin antibody, crizanlizumab ...

  9. After a hearing Friday in San Jose, California, Holmes and Balwani lost a bid to block the Justice Department from combing through more than 200,000 company documents. The judge also ordered ...

  10. 5 Health Care Stocks Gurus Are Buying

    GuruFocus.com via Yahoo FinanceOct 02 20:14 PM

    According to the GuruFocus All-In-One Screener , the following health care stocks are popular among guru investors. Warning! GuruFocus has detected 6 Warning Signs with EAT. The company's largest ...

  11. Emergent BioSolutions Inc. EBS announced that it has closed the acquisition of privately held Adapt Pharma, which will add the latter’s Narcan (naloxone hydrochloride) nasal spray to its portfolio ...